About The Journal
  Aims and Scope
  Editorial Board
  Submit a Manuscript 
  Subscription Information
Articles & Issues
  Issue
  Search
For Authors
  Instructions to Authors
  Ethics in Publishing
  Peer Review Process
  Author's Checklist
  Copyright Transfer Form
Contact us
 
 
 
 
Issue
Korean Chemical Engineering Research,
Vol.55, No.2, 180-189, 2017
PVM 및 FBRM 기반 인라인 모니터링을 통한 indomethacin-saccharin 공결정의 생성 메커니즘이해
Understanding the Mechanism of Indomethacin-Saccharin Co-crystal Formation Using In-line Monitoring System based on PVM and FBRM
김바울, 조민용, 최광진
난용성 약물의 용해도를 증가시키고 안정성을 향상하기 위한 제약 공결정은, 미국 FDA가 지난 2016년 8월에 공결정을 solvate의 특별한 경우라고 정의를 수정하면서, 개량신약의 개발에 더욱 박차를 가할 것으로 추측된다. 본 연구에서는 모델 조합으로 잘 알려진 indomethacin-saccharin 공결정을 반용매 방법으로 제조할 때, 인라인 모니터링 기법을 적용하여, 반용매의 주입속도에 따른 indomethacin 준 안정상의 일시적인 생성 및 indomethacin-saccharin 공결정의 생성을 관찰하고 메커니즘을 제안하고자 하였다. 그간 인라인 모니터링을 위해서 매우 다양한 분석도구가 연구되어 왔는데, 본 연구에서는 PVM (particle vision measurement)와 FBRM (focused beam reflectance measurement)를 조합하여 공결정화 공정에서의 변화를 실시간으로 측정하였다. 공결정화 결과물의 오프라인 분석은 PXRD (powder x-ray diffraction)와 DSC (Differential scanning calorimeter)를 이용하여 수행하였다. 반용매의 주입 속도에 따라서 공결정이 생성되는 경로에 분명한 차이가 있음을 관찰하였으며, 이러한 상관 관계의 이해를 통해서 제약학적 특성이 더욱 일정하고 품질이 보증된 indomethacin-saccharin Co-crystal을 얻는 조건을 확립하였다. 본 연구결과, PVM과 FBRM을 조합한 인라인 모니터링은 제약 공결정 제조공정에서 활용성이 매우 높은 기술이라고 할 수 있다.
Pharmaceutical co-crystals primarily to improve the solubility as well as stability of insoluble drug are to be investigated more intensively for IMDs as US FDA has reclassified co-crystal as a special case of solvates in August this year. In this study, we proposed a mechanism of indomethacin-saccharin co-crystal formation and the creation of transient indomethacin meta-stable form using in-line monitoring tools with the addition rate of anti-solvent as a critical process parameter. Among various instruments, we combined PVM (particle vision measurement) and FBRM (focused beam reflectance measurement) for the in-line monitoring of anti-solvent co-crystallization process. The off-line characterization of resulting powders was carried out employing the PXRD (powder x-ray diffraction) and DSC (differential scanning calorimeter). It was observed that the pathway to the final IMC-SAC co-crystal was significantly dependent upon the anti-solvent addition rate. The process conditions to obtain high quality co-crystal powder effectively were established. Consequently, we concluded that in-line monitoring combing the PVM and FBRM should be useful for the in-line monitoring of pharmaceutical co-crystallization processes.
Keywords: Indomethacin (IMC); Saccharin (SAC) Co-crystallization; Anti-solvent; In-line monitoring; FBRM; PVM
[References]
  1. Chang JW, Yang DR, Korean Ind. Chem. News, 10(5), 25, 2007
  2. Sarma B, Chen J, Hsi HY, Myerson AS, Korean J. Chem. Eng., 28(2), 315, 2011
  3. Liu X, Sun D, Wang F, Wu YJ, Chen Y, Wang L, J. Pharm. Sci., 100(6), 3, 2011
  4. Lee MJ, Wang IC, Kim MJ, Kim P, Song KH, Chun NH, Park HG, Choi GJ, Korean J. Chem. Eng., 32(9), 1910, 2015
  5. Genck W, Make The Most of Antisolvent Crystallization, Chemical Processing, Article, Nov 08, 2010.
  6. http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=713.
  7. Surwase SA, Boetker JP, Saville D, Boyd BJ, Gordon KC, Peltonen L, Strachan CJ, Mol. Pharmaceutics, 10, 4472, 2013
  8. Khomane KS, More PK, Raghavendra G, Bansal AK, Mol. Pharmaceutics, 10, 631, 2013
  9. Carpentier L, Decressain R, Desprez S, Descamps M, J. Phys. Chem. B, 110, 457, 2005
  10. Csermely P, Korcsmaros T, Kiss HJ, London G, Nussinov R, Pharmacol. Ther., 138(3), 333, 2013
  11. Stegemann S, Leveiller F, Franchi D, De Jong H, Linden H, Eur. J. Pharm. Sci., 31(5), 249, 2007
  12. Di L, Fish PV, Mano T, Bridging Solubility Between Drug Discovery and Development., Drug Discovery Today, 486-495(2012).
  13. Turner JR, Drug Discovery. In New Drug Development; Springer: New York, pp 21-34(2010).
  14. Li P, Zhao L, Int. J. Pharm., 341, 1, 2007
  15. Baird JA, J. Pharm. Sci., Baird JA, Van Eerdenbrugh B, Taylor LS, A classification System to Assess the Crystallization Tendency of Organic Molecules From Undercooled Melts,” J. Pharm. Sci., 2010, 99 (9), 3787-3806(2010)., 3787, 2010
  16. Engers D, Teng J, Jimenez-Novoa J, Gent P, Hossack S, Campbell C, Thomson J, Ivanisevic I, Templeton A, Byrn S, Newman A, J. Pharm. Sci., 99(9), 3901, 2010
  17. Neervannan S, Expert Opin. Drug Metab. Toxicol., 2(5), 715, 2006
  18. Hancock BC, Zografi G, J. Pharm. Sci., 86(1), 1, 1997
  19. Laitinen R, Lobmann K, Strachan CJ, Grohganz H, Rades T, Int. J. Pharm., 453, 65, 2013
  20. Bhugra C, Pikal MJ, J. Pharm. Sci., 97(4), 1329, 2008
  21. Savolainen M, Kogermann K, Heinz A, Aaltonen J, Peltonen L, Strachan C, Yliruusi J, Eur. J. Pharm. Biopharm., 71(1), 71, 2009
  22. Wu T, Sun Y, Li N, de Villiers MM, Yu L, Langmuir, 23(9), 5148, 2007
  23. Alonzo D, Zhang G, Zhou D, Gao Y, Taylor L, Pharm. Res., 27, 608, 2010
  24. Greco K, Bogner R, Mol. Pharmaceutics, 7(5), 1406, 2010
  25. Andronis V, Yoshioka M, Zografi G, J. Pharm. Sci., 86(3), 346, 1997
  26. Andronis V, Zografi G, J. Non-Cryst. Solids, 271, 236, 2000
  27. Hancock BC, Shamblin SL, Zografi G, Pharm. Res., 12(6), 799, 1995
  28. Borka L, Acta Pharm. Suec., 11, 295, 1974
  29. Lin SY, J. Pharm. Sci., 81(6), 572, 1992
  30. Takiyama H, Minamisono T, Osada Y, Matsuoka M, Chem. Eng. Res. Des., 88(9A), 1242, 2010
  31. Wang X, de Armas HN, Blaton N, Michoel A, den Mooter GV, Int. J. Pharm., 345, 95, 2007
  32. Chen XM, Morris KR, Griesser UJ, Byrn SR, Stowell JG, J. Am. Chem. Soc., 124(50), 15012, 2002
  33. Qi S, Craig DQM, Mol. Pharmaceutics, 9, 1087, 2012
  34. Saeedi M, Akbari J, Morteza-Semnani K, Enayati-Fard R, Sar-Reshteh-dar S, Soleymania A, Iran. J. Pharm. Res., 10(1), 25, 2011
  35. Alsaidan SM, Alsughayer AA, Eshra AG, Drug Dev. Ind. Pharm., 24, 389, 1998
  36. Chun NH, Wang IC, Lee MJ, Jung YT, Lee S, Kim WS, Choi GJ, Eur. J. Pharm. Biopharm., 85(3), 854, 2013
  37. Wang IC, Lee MJ, Sim SJ, Kim WS, Chun NH, Choi GJ, Int. J. Pharm., 450(1-2), 311, 2013
  38. De Beer TR, Baeyens WR, Ouyang J, Vervaet C, Remon JP, Analyst, 131(10), 1137, 2006
  39. Kim JY, Kwon K, Yakhak Hoeji, 57(6), 432, 2013
  40. http://www.dailypharm.com/News/184408.
  41. http://www.yonhapnews.co.kr/bulletin/2016/07/27/0200000000AKR20160727096700017.HTML?input=1195m.
  42. Kelly AL, Gough T, Dhumal RS, Halsey SA, Paradkar A, Int. J. Pharm., 426(1-2), 15, 2012
  43. U. S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070305.pdf).
  44. Su M, Wang L, Sun H, Wang JK, Frontiers of Chemical Engineering in China, 3(3), 282, 2009
  45. Liu X, Sun D, Wang F, Wu YJ, Chen Y, J. Pharm. Sci., 100(6), 2011
  46. Leyssens T, Org. Process Res., 413, 2011
  47. Jia CY, Yin QX, Zhang MJ, Wang JK, Shen ZH, “Polymorphic Transformation of Pravastatin Sodium Monitored Using Combined Online FBRM and PVM,” Organic Process Research & Development, 12(6), (2008).
참고문헌정보(참고문헌, 인용문헌)는 화학공학소재연구정보센터에 의해 제공되고 있습니다.